PMID- 15563741
OWN - NLM
STAT- MEDLINE
DCOM- 20050503
LR  - 20131121
IS  - 0300-7995 (Print)
IS  - 0300-7995 (Linking)
VI  - 20 Suppl 2
DP  - 2004
TI  - Use of the lidocaine patch 5% in reducing intensity of various pain qualities 
      reported by patients with low-back pain.
PG  - S5-12
AB  - OBJECTIVE: To determine the impact of the lidocaine patch 5% on pain qualities 
      associated with low-back pain (LBP) through use of the Neuropathic Pain Scale 
      (NPS). PATIENTS AND METHODS: Patients were enrolled in an open-label, 
      non-randomized, prospective, 6-week study involving 8 clinical trial sites in the 
      United States. Eligible patients had non-radicular LBP and reported 
      moderate-to-severe pain on the NPS at study enrollment. Patients were stratified 
      to 3 groups based on the duration of their LBP, defined as acute/sub-acute (< 3 
      months), short-term chronic (3-12 months), or long-term chronic LBP (> 12 
      months). The lidocaine patch 5% was applied to the area of maximal pain, using no 
      more than a total of 4 patches changed every 24 h. Effectiveness was measured by 
      change from baseline to Week 2 and Week 6 in 4 composite measures of the NPS: 
      NPS-10, NPS-4, NPS-8, and NPS-non-allodynia. Safety was assessed by adverse 
      events (AEs), dermal assessment of application site(s), and skin sensory testing. 
      RESULTS: In the combined patient population (n = 71), 6 weeks of treatment with 
      lidocaine patch 5% significantly improved all 4 NPS composite measures at both 
      Week 2 and Week 6 (p < 0.001). Separate analyses by subgroups revealed 
      differential improvements in the 4 composite measures. Eleven patients (15.5%) 
      experienced treatment-related AEs that were primarily mild-to-moderate and dermal 
      in nature. CONCLUSIONS: In patients with moderate-to-severe LBP, 2 weeks and 6 
      weeks of treatment with the lidocaine patch 5% significantly reduces the 
      intensity of pain qualities as measured by all 4 NPS composite measures. 
      Lidocaine patch 5% is well tolerated with few systemic AEs and may provide 
      beneficial pain relief for patients receiving multidisciplinary treatment without 
      increasing risks for adverse drug interactions. Pain scales such as the NPS offer 
      the ability to measure various pain qualities experienced by LBP patients and may 
      allow clinicians to assess the treatment impact of different medications.
FAU - Galer, Bradley S
AU  - Galer BS
AD  - Endo Pharmaceuticals, Inc, Chadds Ford, PA 19317, USA. Galer.Bradley@Endo.com
FAU - Gammaitoni, Arnold R
AU  - Gammaitoni AR
FAU - Oleka, Napoleon
AU  - Oleka N
FAU - Jensen, Mark P
AU  - Jensen MP
FAU - Argoff, Charles E
AU  - Argoff CE
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Anesthetics, Local)
RN  - 98PI200987 (Lidocaine)
SB  - IM
MH  - Administration, Cutaneous
MH  - Anesthetics, Local/*administration & dosage
MH  - Female
MH  - Humans
MH  - Lidocaine/*administration & dosage
MH  - Low Back Pain/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Pain Measurement/*methods
MH  - Pilot Projects
MH  - Prospective Studies
MH  - Treatment Outcome
MH  - United States
EDAT- 2004/11/27 09:00
MHDA- 2005/05/04 09:00
CRDT- 2004/11/27 09:00
PHST- 2004/11/27 09:00 [pubmed]
PHST- 2005/05/04 09:00 [medline]
PHST- 2004/11/27 09:00 [entrez]
AID - 10.1185/030079904X12933 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2004;20 Suppl 2:S5-12. doi: 10.1185/030079904X12933.